Exelixis, Inc. (BIT:1EXEL)

Market Cap	10.81B +16.8%
Revenue (ttm)	2.06B +3.3%
Net Income	722.83M +29.5%
EPS	2.62 +37.2%
Shares Out	n/a
PE Ratio	14.96
Forward PE	12.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	43.60
Previous Close	43.60
Day's Range	43.60 - 43.60
52-Week Range	29.27 - 44.67
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 5, 2026

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 1,077
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1EXEL

Financial Performance

In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.

Financial numbers in USD